Purchase O-DSMT
Discount program, second-order - 5%OFF, third-order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy O-DSMT for sale
Desmetramadol, sometimes referred to as O-desmethyltramadol (O-DSMT), is a potent opioid analgesic and tramadol's principal active metabolite. It is a potent analgesic frequently used to treat moderate to severe pain, but its effects are unpredictable due to its unique metabolism and interaction with the human body. This article will examine the characteristics, mode of action, and effects of Desmetramadol on the human body. We will also investigate the involvement of the liver enzyme CYP2D6 in the metabolism of tramadol and why specific individuals may suffer fewer analgesic effects.
The Science of Desmetramadol
Desmetramadol is a potent opioid analgesic and tramadol's principal active metabolite. Similar to codeine, it is created when the liver enzyme CYP2D6 demethylates tramadol. This specific method of action results in a ceiling impact (depending on the availability of CYP2D6) that restricts the therapeutic effects of tramadol to moderate pain therapy.
Desmetramadol relieves pain by binding to mu-opioid receptors in the central nervous system, diminishing pain experience. Compared to other opioid analgesics, such as morphine and fentanyl, it also has a lesser potential for misuse and dependency.
The Role of CYP2D6 in Desmetramadol Metabolism
Desmetramadol is the primary active metabolite of tramadol, which is demethylated by the liver enzyme CYP2D6. However, this process is very varied and can be altered by various variables, including heredity, age, and other drugs.
Those with a less active version of CYP2D6 are referred to as "low metabolizers." These patients experience less analgesic effects with tramadol, resulting in a ceiling effect that restricts the drug's therapeutic advantages. This is because the Desmetramadol generated by the liver in these individuals is less able to bind to the mu-opioid receptors in the central nervous system, resulting in less pain relief and an increased risk of adverse effects.
The Variability of Desmetramadol Effects
Due to Desmetramadol's unusual metabolism and interaction with the human body, its effects can be very unpredictable. This variation is caused by distinct types of CYP2D6 in different individuals, in addition to age, genetics, and other variables.
This heterogeneity in effects can make it difficult to estimate the therapeutic advantages of Desmetramadol for particular individuals, leading to decreased effectiveness or more significant adverse effects. Before providing Desmetramadol, healthcare professionals must carefully assess the patient's medical history, especially any liver or renal illness history.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
500g $1080
1kg $1690
1kg $1690
100g $550
100g $390
100g $490
100g $490
300g $840
200g $690
500g $1390
out of stock
100g $510